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Abstract
Background: Class III β-tubulin, Sox2, and Survivin play important roles in tumor survival and proliferation.
However, the association of these three factors with clinicopathological characteristics, chemoresistance, and
survival in patients with ovarian cancer remains controversial.
Methods: We investigated the predictive value and correlation among the expression levels of Class III β-tubulin,
Sox2, and Survivin in 110 patients with stage III ovarian epithelial cancer, including 58 patients who received
taxane-based chemotherapy and 52 patients who received non-taxane-based chemotherapy. Expression of these
three factors was immunohistochemically examined in 110 ovarian tumor tissues obtained from patients before
chemotherapy.
Results: The positive expression rates for Class III β-tubulin, Sox2, and Survivin in ovarian tumor tissues were
59.09 %, 61.82 % and 52.73 %, respectively. The expression of nuclear Survivin and Class III β-tubulin was consistent
with that of Sox2 (p = 0.005 and 0.020, respectively). Positive expression of Class III β-tubulin, Sox2, and nuclear
Survivin was significantly associated with chemoresistance to taxane-based chemotherapy (p = 0.006, 0.007, and
0.009, respectively), but not to non-taxane-based chemotherapy. Additionally, overexpression of Class III β-tubulin,
Sox2, and nuclear Survivin predicted poor progression-free survival in patients receiving taxane-based
chemotherapy (p = 0.032, 0.005, and 0.004, respectively).
Conclusions: These findings suggest that overexpression of Class III β-tubulin, Sox2, and nuclear Survivin might be
predictive of taxane resistance and poor progression-free survival in patients with stage III ovarian epithelial cancer.
Expression of these three factors may show positive correlations in these patients.
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Background
Ovarian cancer is regarded as the most lethal gyneco-
logic malignancy and ranks as the seventh leading cause
of cancer death among women [1]. The majority of pa-
tients with ovarian cancer are diagnosed at an advanced
stage. Patients treated with standard therapies such as
cytoreductive surgery and chemotherapy often experi-
ence tumor progression and poor survival, which may
be due to intrinsic or acquired chemoresistance. In the
past few decades, much research has been performed to
identify predictive markers for ovarian cancer.
Class III β-tubulin has been linked to taxane resistance
through a reduced microtubule polymerization rate. In
1997, Maria Kavallaris’s group first reported altered ex-
pression of specific β-tubulin genes in taxol resistant
ovarian tumors and proposed that the class III and IVa
isotypes of β-tubulin may play a role in clinical resist-
ance to paclitaxel [2]. Several recent studies also sug-
gested that the overexpression of Class III β-tubulin was
related to paclitaxel resistance in ovarian cancer cell
lines [3, 4].
The transcription factor sex-determining region Y
box2 (Sox2), located on chromosome 3q26.3-q27 [5],
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plays a pivotal role in maintaining self-renewal and
pluripotency of cancer stem cells (CSCs) and regulating
tumor cell survival [6]. Persistence of CSCs could be
detected in mouse ovarian cancer cells after paclitaxel/
carboplatin chemotherapy, and may lead to tumor re-
currence [7]. A study using human ovarian cancer cell
lines also suggested that the expression of Sox2 might
account for cellular resistance to paclitaxel, cisplatin,
and carboplatin [8].
Survivin, the smallest member of the inhibitor of apop-
tosis protein family, prevents programmed cell death [9].
Similar to Class III β-tubulin, Survivin also interacts with
microtubules of the mitotic spindle to oppose the action of
taxane, which blocks cell division by stabilizing microtu-
bules in the G2/M phase [10]. One in vitro study demon-
strated that silencing of Survivin could increase the
sensitivity of ovarian cancer cells to paclitaxel, but not to
cisplatin [3, 11].
Interestingly, knockdown of the Sox2 gene inhibited
androgen-independent prostate cancer cell proliferation
and induced apoptosis through downregulation of the
Survivin gene [12]. Similar results were observed in hu-
man non-small-cell lung cancer cells [6]. Furthermore,
overexpression of Sox2, induced by upregulation of
Survivin, could maintain the survival and homoeostasis
of neural stem cells [13]. Additionally, several researchers
have reported that the transcriptions of Class III β-
tubulin, Sox2, and Survivin could be induced by a
common factor—hypoxia inducible factor—a key inter-
mediate factor in the evolution of cancer [14–17]. These
studies underscore the necessity of exploring the correl-
ation between Sox2, its potential target gene Survivin, and
Class III β-tubulin in ovarian cancer.
Although efforts have been made to delineate the rela-
tionship between these three factors and ovarian cancer
[3, 4, 18–28] or other carcinomas [29–36], consensus
conclusions still could not be reached because of contra-
dictory results. The main reason for such discrepancy is
probably the fact that most of these studies incorporated
patients with some heterogeneity with respect to (1)
clinical stage, (2) surgery patterns, (3) post-operative
chemotherapy, (4) receipt of neoadjuvant chemotherapy,
(5) evaluated index, (6) mRNA and/or protein level. Any
of these factors could account for the unreliable or in-
consistent results. Moreover, the correlations among
Sox2, Survivin, and Class III β-tubulin have not been in-
vestigated among ovarian cancer. In addition, there are
not enough data on the prognostic value of these three
factors specifically in Chinese patients.
We performed a retrospective study of patients with stage
III ovarian epithelial cancer (SOEC) who were treated with
taxane-based or non-taxane-based chemotherapies. We in-
vestigated the correlations among Class III β-tubulin, Sox2,
and Survivin, and the relationship between expression of




The study was performed using ovarian tumor tissues
obtained from 110 consecutive patients with ovarian epi-
thelial cancer in the Tumor Center and Department of
Gynecology, Qilu Hospital of Shandong University, be-
tween 2000 and 2012. The Ethics Committee of Qilu
Hospital approved this protocol, and all patients gave
written informed consent. All patients met the following
eligibility criteria: (1) classified stage III disease accord-
ing to International Federation of Gynecologists and
Obstetricians and the World Health Organization; (2)
received at least two cycles of taxane-based or non-
taxane-based chemotherapy beginning 2–3 weeks after
primary cytoreductive surgery; (3) did not receive neoad-
juvant chemotherapy before primary cytoreductive
surgery. Administration of alternative chemotherapy reg-
imens was mainly based on National Comprehensive
Cancer Network guidelines, with consideration of ana-
phylaxis to taxane, the patients’ economic factors, and
systematic practice variations in different treatment
areas. The clinicopathologic characteristics of all patients
are listed in Table 1.
All patients received a median of six cycles of chemo-
therapy using a 21-day cycle after the primary cytore-
ductive surgery: 58 patients were treated with taxane-
based chemotherapy (defined as the taxane-based
group), i.e., PT (135–175 mg/m2 paclitaxel or 75 mg/
m2 docetaxel on day 1 plus carboplatin dosed with an
area under the curve of 4–6 or 75 mg/m2 cisplatin on
day 2), and 52 patients were treated with non-taxane-
based chemotherapy (defined as the non-taxane-based
group), i.e., PC (carboplatin dosed with an area under
the curve of 4–6 or 75 mg/m2 cisplatin on day 1 plus
750 mg/m2 cyclophosphamide on day 1), PAC (50 mg/
m2 cisplatin on day 1 plus 550 mg/m2 cyclophospha-
mide on day 1 plus 35 mg/m2 doxorubicin on day 1), or
TC (75 mg/m2 cisplatin on day 1 plus 0.75 mg/m2
topotecan on days 1–5).
Response to chemotherapy was evaluated according to
the Response Evaluation Criteria in Solid Tumor
(RECIST, version 1.1), which includes complete response
(CR), partial response (PR), stable disease (SD), and pro-
gression of disease (PD). Progression-free survival (PFS)
was calculated as the time from the start of chemother-
apy to tumor progression or the last follow-up. Overall
survival (OS) was calculated as the time from the begin-
ning of chemotherapy to death or the last follow-up
[33]. In this study, the median follow-up time was
35 months (range, 7–154 months).
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Immunohistochemistry
Paraffin-embedded sections of ovarian cancer tissue were
obtained during primary cytoreductive surgery for all
cases. Slides were deparaffinized, rehydrated, subjected to
epitope retrieval, and treated with H2O2 to block en-
dogenous peroxidase activity. The slides were incubated
with normal rabbit or goat serum, followed by incubation
with a polyclonal goat anti-Sox2 antibody (AF2018, RD
Systems, USA), a monoclonal rabbit anti-Survivin anti-
body (ab76424, Abcam, USA), and a monoclonal rabbit
anti-Class III β-tubulin antibody (ab52623, Abcam, USA),
overnight at 4 °C. Detection was performed using the
Streptavidin/Peroxidase kit, Polymer HRP Detection sys-
tem and DAB kit. Slides were counterstained with
hematoxylin and dehydrated with alcohol and xylene.
Positive controls were provided by slides taken from gli-
oma tissues for Sox2 and Class III β-tubulin, and from
colon cancer tissue for Survivin. Negative controls were
provided by replacing the primary antibody with
phosphate-buffered saline.
The intensity of staining and the percentage of stained
cells were evaluated under a light microscope by three
independent pathologists without knowledge of clinical
data. The intensity of staining was evaluated as follows:
1 = weak staining, 2 = moderate staining, 3 = strong
staining. The percentage of stained cells was categorized
as follows: 0 = 0 % positive cells, 1 = 1–10 % positive
cells, 2 = 11–35 % positive cells, 3 = 36–65 % positive
cells, 4 = 66–100 % positive cells. The total score of
stained cells was calculated by the sum of above two
scores, where grade 0 = 0, grade 1 = 2–3, grade 2 = 4, grade
3 = 5, grade 4 = 6–7. Tumor tissues with grade 2–4 were
defined as positive expression and those with grade 0–1 as
negative expression.
Statistical analysis
Associations between expression of the three factors
(Class III β-tubulin, Sox2, and Survivin) and clinicopath-
ologic characteristics or response to chemotherapy were
tested using χ2 test or Fisher’s exact test, as appropriate.
Survival curves were estimated using the Kaplan–Meier
method, and differences in PFS and OS of two sub-
groups were evaluated using the log-rank test. Cox re-
gression was used for univariate analysis and multivariate
analysis to evaluate the prognostic value of the three fac-
tors for survival. Only variables with P < 0.10 in the uni-
variate analysis were included in the multivariate model.
All statistical analyses were carried out using SPSS 13.0.
Results
Expression of Class III β-tubulin, Sox2, and Survivin
Among the 110 cases, 65 (59.09 %), 68 (61.82 %), and 58
(52.73 %) were positive for expression of Class III β-
tubulin, Sox2, and Survivin, respectively. As shown in
Fig. 1, the expression of Class III β-tubulin and Sox2
was detected in both the cytoplasm and nucleus in all
Table 1 Clinicopathologic characteristics of 110 SOEC patients
Characteristics Total no. Taxane-based group Non-taxane-based group P
Total no. 110 58 52
Median age (range) 54 (21–76) 54 (30–76) 54 (21–73)
Age (years) 0.437
<65 94 51 43
≥65 16 7 9
Histotype 0.095
Serous 84 48 36
Othersa 26 10 16
Grade 0.120
G1-2 38 21 17
G3 72 37 35
Ascites (mL) 0.193
<1000 67 32 35
≥1000 43 26 17
Residual tumor at surgery (cm) 0.513
<1 43 21 22
≥1 67 37 30
Median cycle of chemotherapy (range) 6 (2–8) 6 (2–8) 6 (2–8)
aOvarian endometrioid carcinoma, 11 cases; ovarian mucous carcinoma, 4 cases; ovarian clear cell carcinoma, 1case; ovarian malignant mixed müllerian tumor, 1
case; ovarian mixed adenocarcinoma, 9 cases
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cases. The expression of Survivin differed among cases: 35
cases (60.34 %) showed expression only in the nucleus, 9
(15.52 %) only in the cytoplasm, and 14 (24.14 %) in both
the nucleus and cytoplasm.
It should be mentioned that the expression of nuclear
Survivin and Class III β-tubulin was significantly linearly
correlated with that of Sox2 (p = 0.005 and 0.020), as
shown in Table 2. However, cytoplasmic Survivin did
not show a similar association with Sox2 (p = 0.307).
Associations between expression of Class III β-tubulin,
Sox2, and Survivin and clinicopathologic characteristics
and response to chemotherapy
As shown in Table 3, expression of Class III β-tubulin,
Sox2, and Survivin was not significantly correlated with
age, histotype, grade, ascites, or residual tumor (p > 0.05).
The relationships between these three factors and re-
sponse to chemotherapy are shown in Table 4. In the
taxane-based group, positive expression of Class III β-
tubulin, Sox2, and only nuclear Survivin was signifi-
cantly associated with disease progression (p = 0.006,
0.007, and 0.009, respectively). However, in the non-
taxane-based group, no significant associations between
expression of these three factors and response to chemo-
therapy was demonstrated (p > 0.05).
Survival analysis
In the taxane-based group, progression-free survival
(PFS) data were available for 57 patients (98.28 %), and
the median PFS was 13 months. The Kaplan–Meier
curves in Fig. 2 show that positive expression of Class III
β-tubulin (A), Sox2 (B), and only nuclear Survivin (C)
Fig. 1 Representative pictures by immunochemistry for Class III β-tubulin, Sox2, and Survivin in 110 SOEC patients. Magnification 400×. Class III
β-tubulin expression: (a) negative expression in serous carcinoma, (b) low expression in serous carcinoma, (c) high expression in clear carcinoma.
Sox2 expression: (d) negative expression in serous carcinoma, (e) low expression in serous carcinoma, (f) high expression in mucous carcinoma.
Survivin expression: (g) only nuclear expression in serous carcinoma, (h) only cytoplasmic expression in serous carcinoma, (i) both nuclear and
cytoplasmic expression in serous carcinoma
Table 2 Correlations among Class III β-tubulin, Sox2, and
Survivin in 110 SOEC patients
Total no. Sox2 positive Sox2 negative Pa
Nuclear Survivin 0.005*
Total no. 101 62 39
Positive 49 37 12
Negative 52 25 27
Cytoplasmic Survivin 0.307
Total no. 75 39 36
Positive 23 14 9
Negative 52 25 27
Class III β-tubulin 0.020*
Total no. 110 68 42
Positive 65 46 19
Negative 45 22 23
aCalculated by χ2 test
*P < 0.05
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Table 3 Associations between expression of Class III β-tubulin, Sox2, and Survivin and clinicopathologic characteristics in 110 SOEC
patients




Pa Only nuclear Survivin positive/
negative
Pa Only cytoplasmic Survivin
positive/negative
Pa
Total no. 65/45 68/42 35/52 9/52
Age (years) 0.424 0.620 0.707 1.000
<65 57/37 59/35 30/43 8/43
≥65 8/8 9/7 5/9 1/9
Histotype 0.097 0.176 0.733 0.224
Serous 46/38 49/35 28/40 5/40
Others 19/7 19/7 7/12 4/12
Grade 0.101 0.202 0.396 1.000
G1-2 19/20 47/24 11/21 3/21
G3 46/25 10/5 24/31 6/31
Ascites (mL) 0.814 0.568 0.371 0.725
<1000 39/28 40/27 18/30 6/30
≥1000 26/17 28/15 17/19 3/22
Residual tumor (cm) 0.575 0.299 0.305 0.279
<1 24/19 24/19 11/22 6/22
≥1 41/26 44/23 24/30 3/30
aCalculated by χ2 test, and Fisher’s exact test as appropriate
Table 4 Associations between expression of Class III β-tubulin, Sox2, and Survivin and response to chemotherapya in 100 SOEC
patients
Taxane-based group Non-taxane-based group
Total no. PR PD Pb Total no. PR PD Pb
Class III β-tubulin 0.006* 0.145
Total no. 57 34 23 43 33 10
Positive 34 15 19 24 16 8
Negative 23 19 4 19 17 2
Sox2 0.007* 0.480
Total no. 57 34 23 43 33 10
Positive 40 19 21 25 18 7
Negative 17 15 2 18 15 3
Only nuclear Survivin 0.009* 0.390
Total no. 41 24 17 37 30 7
Positive 19 7 12 14 10 4
Negative 22 17 5 23 20 3
Only cytoplasmic Survivin 0.580 0.495
Total no. 27 20 7 27 23 4
Positive 5 3 2 4 3 1
Negative 22 17 5 23 20 3
aResponse to chemotherapy in 100 SOEC patients includes partial response (PR) and progression of disease (PD). There were no patients with complete response
(CR) or stable disease (SD)
bCalculated by χ2 test
*P < 0.05
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was associated with poor PFS (p = 0.032, 0.005 and
0.004, respectively). However, expression of only cyto-
plasmic Survivin (D) was not related to PFS (p = 0.727).
The median PFS for patients with positive expression of
Class III β-tubulin, Sox2, only nuclear Survivin and only
cytoplasmic Survivin was 9.5, 9.5, 8, and 13 months, re-
spectively; the median PFS for non-expressors of Class
III β-tubulin, Sox2, only nuclear Survivin and only cyto-
plasmic Survivin was 15, 12, 15, and 15 months, respect-
ively. The ratio of PFS for expressors and non-expressors
of Class III β-tubulin, Sox2, only nuclear Survivin, and
only cytoplasmic Survivin was 1.58, 1.58, 1.26, and 1.15,
respectively.
The prognostic value of Class III β-tubulin, Sox2, and
Survivin for PFS in the taxane-based group was also
evaluated using univariate and multivariate analysis
(Table 5). The univariate model indicated that residual
tumor diameter >1 cm and positive expression of Class
III β-tubulin, Sox2, and nuclear Survivin were associated
with shorter PFS (p = 0.001, 0.042, 0.009, and 0.047, re-
spectively). In multivariate analysis, residual tumor,
Class III β-tubulin, and Sox2 remained as unfavorable
Fig. 2 Kaplan-Meier analysis for progression-free survival (PFS) in 57 SOEC patients treated with taxane-based chemotherapy. Positive expression
of Class III β-tubulin (a), Sox2 (b), and only nuclear Survivin (c) was associated with poor PFS (p = 0.032, 0.005, and 0.004, respectively). Expression
of only cytoplasmic Survivin (d) was not related to PFS (p = 0.727). Number of patients at risk at the beginning of each year is shown below the
horizontal axis
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independent prognostic variables for PFS (p = 0.002,
0.038, and 0.047, respectively).
In the non-taxane-based group, PFS data were avail-
able for 41 patients (78.85 %), and the median PFS was
20 months. Kaplan–Meier curves showed no significant
associations between the three proteins and PFS [p = 0.408,
0.182, 0.386 and 0.965 for Class III β-tubulin (A), Sox2 (B),
only nuclear Survivin (C), and only cytoplasmic Survivin
(D), respectively]. The survival curves are shown in
Additional file 1: Figure S1.
The overall survival (OS) of 98 patients (89.09 %) has
been followed, and death occurred in 78 cases (79.59 %).
The median OS for patients who received a taxane-based
regimen was 55 months, and that for patients who re-
ceived a non-taxane-based regimen was 58 months. No
significant associations were observed between expression
of the three proteins and OS of 98 patients using Kaplan–
Meier analysis [p = 0.284, 0.138, 0.428, and 0.503 for Class
III β-tubulin (A), Sox2 (B), the only nucear Survivin (C),
and the only cytoplasmic Survivin (D), respectively]. The
survival curves are shown in Additional file 2: Figure S2.
Potential prognostic factors for OS in all the 98
available patients were also evaluated by univariate
and multivariate analysis (Table 6). Significant inde-
pendent factors were response to chemotherapy, histo-
type, and residual tumor size (p < 0.0001, p = 0.002,
and 0.010, respectively).
Discussion
This retrospective study explored the predictive value of
expression of Class III β-tubulin, Sox2, and Survivin, and
correlations among these proteins in 110 SOEC patients
Table 5 Univariate and multivariate Cox analysis of predictive factors for progression-free survival in 57 SOEC patients treated with
taxane-based chemotherapy
Variables Univariate Multivariate
HR (95 % CI) χ2 P HR (95 % CI) χ2 P
Age (years) 0.669 (0.282-1.586) 0.835 0.361 - - -
<65
≥65
Histotype 1.458 (0.720-2.950) 1.099 0.295 - - -
Serous
Others
Grade 1.244 (0.759-2.041) 0.750 0.386 - - -
G1-2
G3
Ascites (mL) 0.990 (0.552-1.774) 0.001 0.973 - - -
<1000
>1000
Residual tumor (cm) 3.333 (1.650-6.732) 11.266 0.001* 3.050 (1.499-6.205) 9.471 0.002*
<1
≥1
Class III β-tubulin 1.870 (1.022-3.423) 4.121 0.042* 1.915 (1.036-3.538) 4.301 0.038*
Positive
Negative
Sox2 2.623 (1.273-5.407) 6.829 0.009* 2.100 (1.009-4.373) 3.935 0.047*
Positive
Negative
Nuclear Survivin 1.838 (1.009-3.349) 3.959 0.047* - - -
Positive
Negative
Cytoplasmic Survivin 0.958 (0.495-1.852) 0.016 0.898 - - -
Positive
Negative
HR hazard ratios, CI confidence interval
*P < 0.05; only variables with P < 0.10 in the univariate analysis were included in the multivariate model
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who were treated with taxane- or non-taxane-based
chemotherapy.
Our results demonstrated that positive expression of
Class III β-tubulin was associated with disease progres-
sion in SOEC patients receiving taxane-based therapy,
which is in line with previous studies [2, 21]. Further-
more, we found a correlation between overexpression of
Class III β-tubulin and a shorter PFS in SOEC patients
treated with taxane-based chemotherapy. Our results
also suggested no significant relevance of Class III β-
tubulin expression with response in patients who re-
ceived non-taxane-based therapy. The Class III β-
tubulin expression was not correlated with OS in the
whole patient population. By defining disease progres-
sion under chemotherapy as chemoresistance [33, 34,
37], we found that overexpression of Class III β-tubulin
was related to taxane resistance in SOEC patients. How-
ever, Ferrandina et al. reported that the Class III β-
tubulin overexpression predicted a shorter OS and had
no influence on taxane-based chemotherapy in patients
with unresectable ovarian cancer [19]. Thus, Class III β-
tubulin expression may present different biological char-
acteristics in unresectable and resectable patients. More-
over, recent studies reported contradictory results
regarding the predictive value of Class III β-tubulin for
OS through immunohistochemistry or qRT-PCR tests in
Table 6 Univariate and multivariate Cox analysis of predictive factors for overall survival in 98 SOEC patients
Variables Univariate Multivariate
HR (95 % CI) χ2 P HR (95 % CI) χ2 P
Age (years) 1.176 (0.530-2.611) 0.159 0.690 - - -
<65
≥65
Histotype 1.390 (0.969-1.993) 3.198 0.074 2.015 (1.296-3.134) 9.680 0.002*
Serous
Others
Grade - - -
G1-2 1.318 (0.862-2.016) 1.627 0.202
G3
Ascites (mL) 1.021 (0.576-1.811) 0.005 0.943 - - -
<1000
>1000
Residual tumor (cm) 3.814 (1.946-7.476) 15.204 <0.0001* 2.736 (1.271-5.890) 6.617 0.010*
<1
≥1
Response to chemotherapy 5.627 (3.078-10.289) 31.483 <0.0001* 5.318 (2.677-10.564) 22.770 <0.0001*
PR
PD
Class III β-tubulin 1.347 (0.776-2.339) 1.119 0.290 - - -
Positive
Negative
Sox2 1.537 (0.863-2.736) 2.128 0.145 - - -
Positive
Negative
Nuclear Survivin 1.399 (0.813-2.407) 1.472 0.225 - - -
Positive
Negative
Cytoplasmic Survivin 1.206 (0.643-2.261) 0.341 0.559 - - -
Positive
Negative
HR hazard ratios, CI confidence interval
*P < 0.05; only variables with P < 0.10 in the univariate analysis were included in the multivariate model
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patients with stage I–IV ovarian cancer [4, 18, 20]. In
general, it appears that different detection methods at
the protein or mRNA level, as well as different clinical
stages and chemotherapy regimens, may affect the iden-
tification of biomarkers.
The positive expression of Sox2 in the nucleus ob-
served in the present study was in accordance with two
previous studies [38, 39], but contradicted another study
showing Sox2 expression in the cytoplasm [40]. It
should be mentioned that we evaluated the predictive
value of Sox2 in SOEC patients who received taxane- or
non-taxane-based chemotherapy, which provides more
detailed information than studies without subgroup ana-
lysis according to the type of chemotherapy [38, 39].
Our results showed that positive expression of Sox2 was
correlated with chemoresistance and a shorter PFS in
SOEC patients receiving taxane, whereas Sox2 expres-
sion had no significant relevance for response and PFS
in patients receiving non-taxane-based chemotherapy.
Thus, our study indicated a relationship between Sox2
and taxane-resistance in SOEC patients. However, Zhang
et al. did not find an association between Sox2 and che-
moresistance, probably due to heterogeneity of chemo-
therapies administered [38]. We also found that Sox2
was not a potential biomarker for OS, which was in ac-
cordance with data from Zhang’s group [38]. In contrast,
Pham et al. reported that positive expression of Sox2
predicted a longer survival time in patients with stage
II–IV and high-grade ovarian cancer [39]. These distinc-
tions may be explained by differences in clinical stage,
histotype, and chemotherapy regimens of patients en-
rolled in different studies.
Similar to several previous reports [41, 42], the present
study indicates that expression of Survivin is predomin-
antly nuclear rather than that of the cytoplasmic. Other
studies have reported that expression of Survivin was
nearly equivalent in nucleus and cytoplasm [26, 43], pre-
dominantly in the cytoplasm [27], or only in the cyto-
plasm [23], which may be due to differences in reagents,
tissues and counting methods used. In contrast to these
studies, we analyzed the expression of only nuclear
Survivin and only cytoplasmic Survivin separately, to ex-
clude any interference of the ratio of nuclear to cytoplas-
mic Survivin. Kaplan–Meier and univariate analyses
showed that overexpression of nuclear Survivin was pre-
dictive of poor response to chemotherapy and short PFS
in SOEC patients who received taxane-based chemother-
apy, but not for those treated with non-taxane-based
chemotherapy. However, the predictive value of nuclear
Survivin for PFS was not significant in multivariate ana-
lysis, perhaps influenced by the sample size and inter-
action with other factors. In general, we proposed that
positive expression of nuclear Survivin might be predict-
ive for taxane-resistance in SOEC patients, expression of
cytoplasmic Survivin has no significant predictive value.
In most cases, it is the nuclear Survivin, rather than the
cytoplasmic Survivin, that sustains cells’ pluripotency
[44, 45], which may support the prognostic value of nu-
clear staining. Neither nuclear Survivin nor cytoplasmic
Survivin was found to be associated with OS in patients.
However, previous studies showed contradictory results
when evaluating the predictive value of Survivin, which
may be due to incorporation of different chemotherapies
and clinical stages [3, 23, 24, 26, 28]. Interestingly,
Vivas-Mejia et al. demonstrated that Survivin-2B was
a prognostic biomarker in taxane-resistant ovarian
epithelial cancer [25]. In light of these inconsistent re-
sults, the subcellular localization and splicing variants
of Survivin should be further investigated.
Our data demonstrated that residual tumor size fol-
lowing primary cytoreductive surgery and histotype were
independent predictive factors for PFS and OS in SOEC
patients, which is in accordance with the features of fa-
vorable tumor biology [19, 46]. However, expression of
Class III β-tubulin, Sox2, and Survivin showed no rela-
tionship with clinicopathologic characteristics and OS.
The fact that some SOEC patients received other therap-
ies when tumor progression was found after first-line
chemotherapy may have some effect on patient charac-
teristics and the expression of these proteins. Thus, we
hypothesized that Class III β-tubulin, Sox2, and nuclear
Survivin may be used to predict chemoresistance, but
not the intrinsic tumor aggressiveness and OS.
Several in vitro studies have reported that Survivin is a
downstream target of Sox2 [6, 12, 13]. Our results for nu-
clear Survivin and cytoplasmic Survivin at the protein
level in ovarian cancer tissues indicated that nuclear
Survivin expression was consist with Sox2 expression.
Moreover, Class III β-tubulin expression also correlated
with Sox2 expression, suggesting the need for further in-
vestigation into the clinical relevance of these associations.
The limitations of our study include the small sample
size and its retrospective nature. The limited number of
patients and missing information of follow-up in terms
of PFS for patients who received non-taxane chemother-
apies (21.15 %) may affect the significance of our results.
A larger number of cases, and mRNA expression of
these potential markers, should be investigated to con-
firm our findings.
Conclusions
Overexpression of Class III β-tubulin, Sox2, and nu-
clear Survivin might predict taxane resistance and poor
progression-free survival in patients with SOEC. Future
prospective studies evaluating these markers in SOEC
patients should be carried out to determine their clin-
ical potential.
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Additional files
Additional file 1: Figure S1. Kaplan-Meier analysis for progression-free
survival (PFS) in 41 SOEC patients treated with non-taxane-based
chemotherapy. There were no significant associations between
expression of the three proteins and PFS [p = 0.408, 0.182, 0.386 and
0.965 for Class III β-tubulin (A), Sox2 (B), only nuclear Survivin (C), and
only cytoplasmic Survivin (D), respectively]. (JPEG 1010 kb)
Additional file 2: Figure S2. Kaplan-Meier analysis for overall survival
(OS) in 98 SOEC patients. There were no significant associations between
expression of the three proteins and OS [p = 0.284, 0.138, 0.428, and 0.503
for Class III β-tubulin (A), Sox2 (B), only nuclear Survivin (C), and only
cytoplasmic Survivin (D), respectively]. (JPEG 1010 kb)
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